Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2018
Oslo, Norway, 27 February 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the fourth quarter and full year 2018. A presentation by the company’s senior management team will take place today in Oslo at 08:30 CET, see details below. Eduardo Bravo, CEO, commented: “We believe we have made solid progress during 2018 advancing the key clinical development programmes for Betalutin® as a single agent and in combination with rituximab in non-Hodgkin’s lymphoma patients. The latest results from the LYMRIT 37-01 trial, presented at ASH in December, continue to highlight